Number of Negative Points: A novel method for predicting radiosensitivity in head and neck tumor cell lines

Oncology Reports

Volumn 20, Issue 2, 2008, Pages 453-461

  Farnebo, Lovisa ^a   Jerhammar, Fredrik ^a   Vainikka, Linda ^a   Grénman, Reidar ^b   Norberg Spaak, Lena ^a   Roberg, Karin ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Epidermal growth factor receptor; p53; Predictive markers; Squamous cell carcinoma; Survivin

Indexed keywords

CYCLIN D1; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; HEAT SHOCK PROTEIN 70; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53; SMAD4 PROTEIN; SURVIVIN;

ADULT; AGED; ANALYTIC METHOD; APOPTOSIS; ARTICLE; CELL GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; MALE; MISSENSE MUTATION; POINT MUTATION; PRIORITY JOURNAL; RADIOSENSITIVITY; RNA SPLICING; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; WESTERN BLOTTING;

ADULT; AGED; ALTERNATIVE SPLICING; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELLS, CULTURED; COLONY-FORMING UNITS ASSAY; CYCLOOXYGENASE 2; DATA INTERPRETATION, STATISTICAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KERATINOCYTES; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIATION TOLERANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR SUPPRESSOR PROTEIN P53;

EID: 48749114572     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or_00000028     Document Type: Article

References (30)

1. Haffty BG and Glazer PM: Molecular markers in clinical radiation oncology. Oncogene 22: 5915-5925, 2003.
2. Lothaire P, De Azambuja E, Dequanter D, et al: Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head Neck 28: 256-269, 2006.
3. Zhan Q, Bae I, Kastan MB and Fornace AJ Jr: The p53-dependent gamma-ray response of GADD45. Cancer Res 54: 2755-2760, 1994.
4. Condon LT, Ashman JN, Ell SR, Stafford ND, Greenman J and Cawkwell L: Overexpression of Bcl-2 in squamous cell carcinoma of the larynx: a marker of radioresistance. Int J Cancer 100: 472-475, 2002.
5. Guo B, Cao S, Toth K, Azrak RG and Rustum YM: Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma. Clin Cancer Res 6: 718-724, 2000.
6. Yu J, Yue W, Wu B and Zhang L: PUMA sensitizes lung cancer cells to chemotherapeutic agents and irradiation. Clin Cancer Res 12: 2928-2936, 2006.
7. Ang KK, Berkey BA, Tu X, et al: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62: 7350-7356, 2002.
8. Eriksen JG, Steiniche T, Askaa J, Alsner J and Overgaard J: The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 58: 561-566, 2004.
9. Hitt R, Ciruelos E, Amador ML, et al: Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. Eur J Cancer 41: 453-460, 2005.
10. Dubois RN, Abramson SB, Crofford L, et al: Cyclooxygenase in biology and disease. FASEB J 12: 1063-1073, 1998.
11. Jones MK, Wang H, Peskar BM, et al: Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 5: 1418-1423, 1999.
12. Thomas GR, Nadiminti H and Regalado J: Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol 86: 347-363, 2005.
13. Deveraux QL and Reed JC: IAP family proteins - suppressors of apoptosis. Genes Dev 13: 239-252, 1999.
14. Altieri DC: Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22: 8581-8589, 2003.
15. Lo Muzio L, Pannone G, Staibano S, et al: Survivin expression in oral squamous cell carcinoma. Br J Cancer 89: 2244-2248, 2003.
16. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E and Kroemer G: Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 5: 2592-2601, 2006.
17. Grady WM: Transforming growth factor-beta, Smads and cancer. Clin Cancer Res 11: 3151-3154, 2005.
18. Pekkola-Heino K, Jaakkola M, Kulmala J and Grenman R: Comparison of cellular radiosensitivity between different localizations of head and neck squamous-cell carcinoma. J Cancer Res Clin Oncol 121: 452-456, 1995.
19. Sundqvist K, Liu Y, Arvidson K, et al: Growth regulation of serum-free cultures of epithelial cells from normal human buccal mucosa. In Vitro Cell Dev Biol 27A: 562-568, 1991.
20. Grenman R, Burk D, Virolainen E, et al: Clonogenic cell assay for anchorage-dependent squamous carcinoma cell lines using limiting dilution. Int J Cancer 44: 131-136, 1989.
21. Erjala K, Pulkkinen J, Kulmala J and Grenman R: Concomitant vinorelbine and radiation in head and neck squamous cell carcinoma in vitro. Acta Oncol 43: 169-174, 2004.
22. Fertil B, Dertinger H, Courdi A and Malaise EP: Mean inactivation dose: a useful concept for intercomparison of human cell survival curves. Radiat Res 99: 73-84, 1984.
23. Roberg K, Jonsson AC, Grenman R and Norberg-Spaak L: Radiotherapy response in oral squamous carcinoma cell lines: evaluation of apoptotic proteins as prognostic factors. Head Neck 29: 325-334, 2007.
24. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951.
25. Zhuang SM, Cochran C, Goodrow T, Wiseman RW and Soderkvist P: Genetic alterations of p53 and ras genes in 1,3-butadiene- and 2′,3′-dideoxycytidine-induced lymphomas. Cancer Res 57: 2710-2714, 1997.
26. Reed JC: Bcl-2 family proteins. Oncogene 17: 3225-3236, 1998.
27. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578, 2006.
28. Iacobuzio-Donahue CA, Song J, Parmiagiani G, Yeo CJ, Hruban RH and Kern SE: Missense mutations of MADH4: characterization of the mutational hot spot and functional consequences in human tumors. Clin Cancer Res 10: 1597-1604, 2004.
29. Erjala K, Pulkkinen J, Kulmala J, Alanen K and Grenman R: Head and neck squamous cell carcinoma is highly sensitive to vinorelbine in vitro. Anticancer Res 22: 3135-3142, 2002.
30. Hauser U, Balz V, Carey TE, et al: Reliable detection of p53 aberrations in squamous cell carcinomas of the head and neck requires transcript analysis of the entire coding region. Head Neck 24: 868-873, 2002.